Filter By:

Choose an area from the filter to limit results to that area and show available options for further filtering

Funding Awarded

7 awards

  • Irish Platform for Patients Organisations Science and Industry Support Award remove from filter
  • Irish Platform for Patients Organisations Science and Industry

    The Irish Platform for Patients' Organisations, Science and Industry (IPPOSI) is a unique organisation in Ireland and abroad. The platform brings together patient groups, scientists, clinicians, industry and other key decision makers to discuss and build consensus on issues relevant to all involved in delivering treatments to people...

  • What is Alpha-1?

    Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic disorder that affects the lungs. Typically people with Alpha-1 present with chronic obstructive pulmonary disease (COPD) or severe asthma. Ireland has one of the highest rates of AATD in the world. 1 in 25 Irish people are carriers for the condition and are at risk of lung disease,...

  • Irish Platform for Patients Organisations Science and Industry

    The Irish Platform for Patients' Organisations, Science and Industry (IPPOSI) is a unique organisation in Ireland and abroad. The platform brings together patient groups, scientists, clinicians, industry and other key decision makers to discuss and build consensus on issues relevant to all involved in delivering treatments to people...

  • Altered lipid raft cholesterol content contributes to the dysregulated activity of neutrophils in alpha-1 antitrypsin deficiency

    Alpha-1-antitrypsin (AAT) deficiency (AATD) is largely unrecognized and under diagnosed. This hereditary disorder results in the rapid progression of lung disease, especially in smokers. Specific treatment for this disorder is available in the form of weekly intravenous injections of AAT. This is referred to as augmentation therapy and...

  • Alpha-1 antitrypsin deficiency: Which is important phenotype, level, activity or all three?

    Alpha-1 antitrypsin (AAT) deficiency (AATD) is generally regarded as a rare condition but more recently, evidence points towards it being a condition that is relatively common but rarely diagnosed. The most severe form of this genetic disorder, where people carry two bad AAT genes (Z) is known as ZZ-AATD and this affects around 2000...

  • Irish Platform for Patients Organisations Science and Industry

    The purpose of this award is to enable IPPOSI to undertake a work programme providing a forum for patient organisations, scientists and industry to inform and support the advancement of health research for the development of therapies and cures for unmet medical needs specifically but not limited to:

    • Providing information...

    • Irish Platform for Patients Organisations Science and Industry

      IPPOSI brings together patient groups, scientists, clinicians, industry and other key decision makers to discuss and build consensus on issues relevant to delivering treatments to people with unmet medical needs. On behalf of the DOH, the HRB has been co-funding IPPOSI with between 40-50% of their annual income since 2007. The...